3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity

• US 8,927,589 B2
• Filed: 03/15/2013
• Issued: 01/06/2015
• Est. Priority Date: 01/26/2005
• Status: Active Grant

• Current Assignee: Allergan Incorporated (Abbvie Incorporated), Exonhit Therapeutics SA (Eurobio-Scientific SA)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Leblond, Bertrand, Beausoleil, Eric, Taverne, Thierry, Donello, John E.
• Primary Examiner(s): Grazier, Nyeemah A
• Application Number:
  US13/834,336
• Publication Number:
  US 20130202653A1
• Time in Patent Office: 662 Days
• Field of Search: None
• US Class Current: 514/422
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim
• CPC Class Codes: A61K 31/4409 only substituted in position 4, e.g. isoniazid, iproniazid
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/5375 1,4-Oxazines, e.g. morpholine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/541 Non-condensed thiazines containing further heterocyclic rings
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07D 207/09 Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• CPC Class Codes: C07D 213/64 attached in position 2 or 6
• CPC Class Codes: C07D 265/30 not condensed with other rings
• CPC Class Codes: C07D 295/12 substituted by singly or doubly bound nitrogen atoms nitro radicals C07D295/06
• CPC Class Codes: C07D 295/13 : to an acyclic saturated chain
• CPC Class Codes: C07D 295/15 : to an acyclic saturated chain
• CPC Class Codes: C07D 319/18 : Ethylenedioxybenzenes, not substituted on the hetero ring
• CPC Class Codes: C07D 405/06 : linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compounds of Formulas 1 and 2

• • where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.

Claims

1. A method for treating chronic pain in a mammal, comprising administering to said mammal at least one compound of the formula:

2. A method for treating chronic pain in a mammal, comprising administering to said mammal at least one compound of the formula:

3. A method for treating chronic pain in a mammal, comprising administering to said mammal a compound of the formula:

4. A method for treating chronic pain in a mammal, comprising administering to said mammal a compound of the formula:

5. A compound of the formula:

9. A pharmaceutical composition comprising at least one compound of claim 5, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

6. A compound of the formula:

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein the compound has the formula:

8. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein the compound has the formula:

10. A pharmaceutical composition comprising at least one compound of claim 6, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.